APEX1 and cancer: Analyses of the full data set indicated a marginally significant association of the APEX1 Asp148Glu polymorphism with cancer risk under allelic (OR=1.05; 95% CI: 0.99-1.11; P=0.071), dominant (OR=1.09; 95% CI: 1.01-1.17; P=0.028), and heterozygous genotypic (OR=1.08; 95% CI: 1.01-1.16; P=0.026) models, with high probabilities of heterogeneity (I2=70.6%, 67.1%, and 59.5% respectively, all P<0.0005 from the χ2 test) (Table 2 and Table 3).